Frank Valone - FibroGen Chief Medical Officer
| FGEN Stock | USD 1.17 0.10 7.87% |
Executive
Dr. Frank H. Valone, M.D. is Senior Fellow, Clinical Development of the Company. since 2016.
| Age | 66 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Address | 409 Illinois Street, San Francisco, CA, United States, 94158 |
| Phone | 415 978 1200 |
| Web | https://www.fibrogen.com |
FibroGen Management Efficiency
The company has return on total asset (ROA) of (0.3554) % which means that it has lost $0.3554 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.1579) %, meaning that it created substantial loss on money invested by shareholders. FibroGen's management efficiency ratios could be used to measure how well FibroGen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 18th of April 2024, Return On Tangible Assets is likely to grow to -0.64. In addition to that, Return On Capital Employed is likely to grow to -1.24. At this time, FibroGen's Total Assets are very stable compared to the past year. As of the 18th of April 2024, Non Current Assets Total is likely to grow to about 146.7 M, while Other Assets are likely to drop 0.95.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| DeNell Mitchell | Home Federal Bancorp | 68 | |
| Kimberly Scholtz | Provident Bancorp | N/A | |
| Denise Gallant | Provident Bancorp | N/A | |
| Jean Kim | Provident Bancorp | 50 | |
| John Batson | Home Federal Bancorp | N/A | |
| Alejandro Miranda | Betterware De Mexico | N/A | |
| Janine Jakubauskas | Provident Bancorp | N/A | |
| Donna Lewis | Home Federal Bancorp | 61 | |
| Dawn FitzgeraldWilliams | Home Federal Bancorp | N/A | |
| Joseph Kenney | Provident Bancorp | N/A | |
| Carlos Doormann | Betterware De Mexico | 53 | |
| Anne Lapointe | Provident Bancorp | N/A | |
| Pilar Sanchez | Betterware De Mexico | N/A | |
| Kevin Barton | Provident Bancorp | N/A | |
| Juan Hernandez | Betterware De Mexico | N/A | |
| Kenneth Fisher | Provident Bancorp | N/A | |
| Mauricio Alvarez | Betterware De Mexico | 54 | |
| Reynaldo VizcarraMendez | Betterware De Mexico | 58 | |
Management Performance
| Return On Equity | -10.16 | ||||
| Return On Asset | -0.36 |
FibroGen Leadership Team
Elected by the shareholders, the FibroGen's board of directors comprises two types of representatives: FibroGen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of FibroGen. The board's role is to monitor FibroGen's management team and ensure that shareholders' interests are well served. FibroGen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, FibroGen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Kearns, Independent Director | ||
| Kirk MBA, Chief Officer | ||
| Rahul Kaushik, Technical Development | ||
| Jorma Routti, Independent Director | ||
| Mr JD, Chief Officer | ||
| Jeffrey Edwards, Director | ||
| Barry Berkowitz, Founder | ||
| James Schoeneck, Independent Director | ||
| David DeLucia, Vice Relations | ||
| Toshinari Tamura, Independent Director | ||
| Jeffrey Henderson, Director | ||
| K Yu, Vice President - Clinical Development | ||
| Peony Yu, Chief Medical Officer | ||
| Gerald Lema, Director | ||
| Juan Graham, Chief Officer | ||
| Roberto Rosenkranz, Independent Director | ||
| Thomas Neff, Founder, Chairman and CEO | ||
| Enrique Conterno, CEO Director | ||
| Frank Valone, Chief Medical Officer | ||
| Kalevi Kurkijarvi, Independent Director | ||
| Christine Chung, Senior Operations | ||
| Suzanne Blaug, Independent Director | ||
| Thane Wettig, CEO Director | ||
| Maykin Ho, Independent Director | ||
| Elias Kouchakji, Drug Devel | ||
| Rory Riggs, Independent Director | ||
| Julian Stern, Corporate Secretary, Director, Member of Audit Committee and Member of Compensation Committee | ||
| KinHung Yu, Chief Medical Officer | ||
| Karen Bergman, Vice President Investor Relations and Corporate Communications | ||
| Tricia Stewart, Chief Officer | ||
| Pat Cotroneo, CFO, Vice President - Finance | ||
| MPH MD, Ex Officer | ||
| John Hunter, Chief Officer |
FibroGen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is FibroGen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.16 | ||||
| Return On Asset | -0.36 | ||||
| Profit Margin | (1.92) % | ||||
| Operating Margin | (3.81) % | ||||
| Current Valuation | 105.24 M | ||||
| Shares Outstanding | 98.77 M | ||||
| Shares Owned By Insiders | 6.36 % | ||||
| Shares Owned By Institutions | 71.45 % | ||||
| Number Of Shares Shorted | 5.19 M | ||||
| Price To Earning | 97.67 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.Note that the FibroGen information on this page should be used as a complementary analysis to other FibroGen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for FibroGen Stock analysis
When running FibroGen's price analysis, check to measure FibroGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FibroGen is operating at the current time. Most of FibroGen's value examination focuses on studying past and present price action to predict the probability of FibroGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FibroGen's price. Additionally, you may evaluate how the addition of FibroGen to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is FibroGen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.536 | Earnings Share (2.92) | Revenue Per Share 1.518 | Quarterly Revenue Growth (0.21) | Return On Assets (0.36) |
The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.